Received Aug 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | UNK | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
patients received Heplisav-B in the end of April and Twinrix on 8.8.25; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of interchange of vaccine products in a male patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included Hepatitis b vaccine rHBsAg (yeast) (Heplisav b) for prophylaxis. On 08-AUG-2025, the patient received Twinrix. In APR-2025, the patient received Heplisav b. On 08-AUG-2025, an unknown time after receiving Twinrix and an unknown time after receiving Heplisav b, the patient experienced interchange of vaccine products (Verbatim: patients received Heplisav-B in the end of April and Twinrix on 8.8.25). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 19-AUG-2025 The pharmacist asked which vaccine give first and how much time in between doses to wait after one of her patients received Heplisav-B in the end of April and Twinrix on 8th August 2025 which led to interchange of vaccine products. The reporter also mentioned that the patient missed a Heplisav-B dose on time, so adverse event details were retrieved.